Review Article
The Role of the Research Advanced Practice Provider in CAR T-Cell Clinical Trials
Ly Dsouza, PA-C, MPAS
From The University of Texas MD Anderson Cancer Center, Houston, Texas
Author’s disclosure of conflict of interest is found at the end of this article.
Correspondence to: Ly Dsouza, PA-C, MPAS, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030
E-mail: ldsouza@manderson.org
J Adv Pract Oncol 2023;14(1):54–66 |
https://doi.org/10.6004/jadpro.2023.14.1.5 |
© 2023 Harborside™
ABSTRACT
In recent years, chimeric antigen receptor (CAR) T-cell therapy has emerged as an effective and potentially paradigm-shifting therapy for patients with refractory lymphoma and myeloma. This novel therapy involves engineering T cells to recognize specific antigens on the surface of cancer cells. Several CAR T-cell products are approved by the US Food and Drug Administration as a result of numerous clinical trials. Due to the complexity of these studies and the high level of care required for CAR T-cell therapy patients, the role of the research advanced practice provider (APP) has become increasingly central to the success of CAR T-cell trials. This review article explores the vital role of the research APP in CAR T-cell clinical trials.
For access to the full length article, please
sign in.
